Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AVROBIO, INC.

(AVRO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société AVROBIO, INC.
01/07AVROBIO : Current Report (Form 8-K)
PU
01/07AVROBIO, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or ..
AQ
01/06AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
01/04Ford, Hess rise; Blackbaud, Avrobio fall
AQ
01/04AVROBIO : Reprioritizes Pipeline Programs - Form 8-K
PU
01/04AVROBIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/04AVROBIO : Pipeline Prioritization and Fabry Data Presentation
PU
01/04AVROBIO Reprioritizes Pipeline Programs
BU
2021AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
2021AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Dat..
BU
2021AVROBIO to Present at Two Upcoming Investor Conferences in November
BU
2021AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(4)
AQ
2021AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference
BU
2021AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
2021AVROBIO, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
2021AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update - For..
PU
2021AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update
BU
2021AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a ..
BU
2021AVROBIO Announces the Appointment of Essra Ridha, M.D., MRCP, FFPM, as Chief Medical Of..
BU
2021AVROBIO : to Present at the Jefferies Virtual Gene Therapy/Editing Summit
BU
2021AVROBIO : Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry ..
PU
2021AVROBIO, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
2021AVROBIO : Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry ..
BU
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
2021AVROBIO : to Present New Clinical and Preclinical Data Across Multiple Programs at the ESG..
BU
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
2021AVROBIO : to Participate at Four Upcoming Investor Conferences
BU
2021AVROBIO : Corporate Presentation August 2021
PU
2021AVROBIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021AVROBIO : Management's Discussion and Analysis of Financial Condition and Results of Opera..
AQ
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635
AQ
2021AVROBIO : Reports Second Quarter 2021 Financial Results and Provides Business Update
BU
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
2021AVROBIO : to Present at Two Upcoming Investor Conferences in August
BU
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
2021AVROBIO : Corporate Presentation June 2021
PU
2021AVROBIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021AVROBIO, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
2021AVROBIO : to Present at the JMP Securities Life Sciences Conference
BU
2021AVROBIO : Announces Inducement Grant Under Nasdaq Listing Rule 5635(4)
AQ
2021AVROBIO : Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
2021AVROBIO : Management's Discussion and Analysis of Financial Condition and Results of Opera..
AQ
2021AVROBIO : Reports First Quarter 2021 Financial Results and Provides Business Update
BU
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
2021ONGOING INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims Aga..
PR
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
2021INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claims Against ..
BU
2021INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims Against AVR..
BU
2021BREAKING ALERT : Rosen Law Firm Encourages AVROBIO, Inc. Investors with Losses to Inquire ..
BU
2021AVROBIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021AVROBIO : Anticipates initiating registration trial with kidney biopsy endpoint in mid-202..
PU
2021AVROBIO : Corporate Presentation May 2021
PU
2021AVROBIO : Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease
BU
2021AVROBIO : to Present Clinical and Preclinical Data at the ASGCT 24th Annual Meeting
BU
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
2021AVROBIO : Corporate Presentation April 2021
PU
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
2021AVROBIO : Corporate Presentation March 2021
PU
2021AVROBIO, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
2021AVROBIO : Management's Discussion and Analysis of Financial Condition and Results of Opera..
AQ
2021AVROBIO : Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Busin..
BU
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
2021AVROBIO : Receives Orphan Drug Designation from the European Commission for AVR-RD-04, an ..
AQ
2021AVROBIO : Receives Orphan Drug Designation from the European Commission for AVR‑RD&#..
BU
2021AVROBIO : to Present at Three Upcoming Investor Conferences in March
BU
2021AVROBIO : Corporate Presentation February 2021
PU
2021AVROBIO : Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in Firs..
AQ
2021AVROBIO, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
2021AVROBIO : Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in Firs..
BU
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
2021AVROBIO : Announces Multiple Clinical Data Presentations, Posters and Events at 17th Annua..
BU
1  2  3Next
Upcoming event on AVROBIO, INC.